Skip to content
HomeLatest newsJohnson & Johnson releases its 2022 Health for Humanity Report and “We All Belong: 2022 DEI Impact Review”
A close-up of a person holding a baby in a pink shirt

Johnson & Johnson releases its 2022 Health for Humanity Report and “We All Belong: 2022 DEI Impact Review”

Together, they detail the company’s ongoing work in helping to create a healthier world, building a more diverse and inclusive workforce, championing global health equity and more.

Share Article
share to

Improving the future of health—for everyone, everywhere—is the driving force behind everything Johnson & Johnson does. Indeed, it reflects a commitment outlined in Our Credo, a set of values that have guided the company’s decision making since 1943: “We are responsible to the communities in which we live and work and to the world community as well.”

The just-released 2022 Health for Humanity Report and We All Belong: 2022 Diversity, Equity and Inclusion (DEI) Impact Review prove the company takes that responsibility seriously through its dedicated implementation of its environmental, social and governance (ESG) strategy. The annual publications detail the company’s progress toward driving sustainable social, environmental and economic change, and creating a healthier, more equitable world.

“The 2022 Health for Humanity Report and We All Belong: 2022 DEI Impact Review detail how Johnson & Johnson, with intention, is accelerating change within our company and the world at large and making progress towards our ambitious goals,” said Joaquin Duato, Johnson & Johnson Chairman of the Board and Chief Executive Officer. “As we reflect on the stories shared within each report, we are also reminded of how much more we can do for the health of humanity and to foster belonging.”

Advancing Health for Humanity

Improving the health and well-being of people around the world requires a mix of heart, science and ingenuity. Johnson & Johnson used that blend of values to set its Health for Humanity Goals in 2020 and made considerable strides toward achieving them in 2022. For example, the company ranked #2 on the Access to Medicines Index, a measurement of Johnson & Johnson’s longstanding commitment to making its lifesaving medicines and innovative technologies available to people in close to 100 low- and middle-income countries.

Last year, alongside the Johnson & Johnson Foundation, the company achieved its Health for Humanity goal of reaching 1 million nurses, midwives and community health workers with support, tools and training, an important milestone given the fact that one in three healthcare providers report experiencing work-related physical and mental stress. To that same end, in 2022 the company invested more than $52 million in programs that support community health centers, empower health workers, spread health education and improve community health programs—all goals of Our Race to Health Equity, which was launched by Johnson & Johnson in 2020. Through the initiative, the company is investing $100 million over five years to support healthcare programs aimed at underserved communities, as well as partnerships that address social determinants of health.
Recognizing that human health and environmental health are inextricably linked, Johnson & Johnson continues to make progress toward reaching its ambitious climate goals. That progress was acknowledged in 2022 with an A-list rating from CDP—the gold standard of environmental reporting—for the fifth consecutive year.

Also in 2022: The company invested $14.6 billion in R&D across its businesses and integrated digital capabilities into how it works.

That’s not all. The company also achieved its Health for Humanity goal of achieving 35% ethnic and racial diversity in management positions within the U.S.

Fostering an Inclusive Work Environment—and World

The just-released DEI Impact Review details Johnson & Johnson’s progress toward building a more diverse and inclusive workforce. Namely, in 2022, the company achieved gender parity in 50% of its regions; 41% of the company’s vice presidents globally are women; and 100% of the more than 26,000 people leaders at Johnson & Johnson have committed to DEI goals that are linked to performance.
The results of the Our Credo employee survey show that attention to inclusivity and diversity hasn’t gone unnoticed: 86% of employees agree that the company provides an inclusive work environment in which each employee is considered an individual. In fact, more than 26,000 employees participate in Johnson & Johnson’s Employee Resource Groups across 496 chapters globally.

Recognizing that DEI extends beyond its walls, the company spent $3.2 billion with Tier 1 diverse suppliers (which include minority- and women-owned businesses), to ensure the company helps create wealth and opportunity across its network of partners.

Combined, the Report and the Review show how Johnson & Johnson continues to build on its legacy of working to change the future of health for all people, all around the world.

Learn more about the 2022 Health for Humanity Report

Read about Johnson & Johnson’s environmental, social and governance progress and performance throughout 2022.

Learn more about We All Belong: 2022 DEI Impact Review

Read about how Johnson & Johnson is holding itself accountable to its long-standing commitment to building a company—and a world—where we all belong.

More from Johnson & Johnson

Giving the gift of sight

In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.

“Lung cancer wasn’t even on my radar. Then I was diagnosed.”

The disease is often detected late—which can have fatal consequences. But thanks to innovations in diagnostic tools, there’s a way to catch lung cancer earlier. Here’s how early detection saved one woman’s life.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.